Tirzepatide vs Retatrutide: Head-to-Head Comparison
Tirzepatide is an FDA-approved dual GIP/GLP-1 agonist achieving up to 22.5% weight loss. Retatrutide is an investigational triple agonist (GIP/GLP-1/glucagon) showing up to 24.2% weight loss in Phase 2 — the highest ever recorded. Tirzepatide is available now; retatrutide is still in Phase 3 trials.
Side-by-Side Comparison
| Dimension | Tirzepatide | Retatrutide |
|---|---|---|
| Evidence Level | Level A — Phase 3 RCTs (SURMOUNT, SURPASS) | Level B — Phase 2 RCT; Phase 3 ongoing |
| FDA Status | Approved for T2D (Mounjaro) and obesity (Zepbound) | Not approved; Phase 3 trials (TRIUMPH program) |
| Weight Loss Efficacy | Up to 22.5% (SURMOUNT-1 at 72 weeks) | Up to 24.2% (Phase 2 at 48 weeks) |
| Mechanism | Dual agonist: GIP + GLP-1 receptors | Triple agonist: GIP + GLP-1 + glucagon receptors |
| Liver Fat Reduction | Moderate liver fat reduction observed | Significant liver fat reduction via glucagon activation |
| Availability | Available by prescription now | Not yet available; expected 2026-2027 |
Peptide Overviews
Tirzepatide
AFDA ApprovedTirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Achieves unprecedented weight loss in clinical trials.
Retatrutide
BHuman StudiesRetatrutide is an investigational triple-hormone receptor agonist developed by Eli Lilly. It simultaneously targets GIP, GLP-1, and glucagon receptors, achieving the highest weight loss ever reported in an obesity clinical trial — up to 24.2% at 48 weeks.
Tirzepatide vs Retatrutide: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.